<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Drug Development on FinanClub</title>
    <link>https://finan.club/tags/drug-development/</link>
    <description>Recent content in Drug Development on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 28 Mar 2024 09:04:22 +0000</lastBuildDate><atom:link href="https://finan.club/tags/drug-development/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Thu, 28 Mar 2024 09:04:22 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-34
Chances: AstraZeneca&amp;rsquo;s obesity drug shows promising results in early-stage study FDA approves AstraZeneca&amp;rsquo;s Ultomiris for AQP4 Ab+ NMOSD, expanding its product portfolio Beijing&amp;rsquo;s efforts to improve business environment and attract foreign firms could benefit AstraZeneca Ionis&amp;rsquo; collaboration revenues enable it to invest in its pipeline, indicating potential growth Risks: Stock price movement has been relatively volatile in the recent trading sessions Potential impact on AstraZeneca&amp;rsquo;s business from China&amp;rsquo;s changing regulatory environment and foreign investment trends Competition in the pharmaceutical industry may pose risks to AstraZeneca&amp;rsquo;s future growth Continued uncertainty in global economic and political conditions could affect AstraZeneca&amp;rsquo;s operations Score:-34 chances characters count - risks characters count = -34</description>
    </item>
    
  </channel>
</rss>
